证券记录 · 已归档季度
AQST
Aquestive Therapeutics, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
13被追踪持有人
+1Δ持有人
18.15M持有股份
$60.07M报告持仓市值
+1新建仓位
−0清仓
动量输入（同类管理人）：
持有人广度 +8.3% ·
股份流向 +15.8% ·
净新建仓位 +7.7%
— 公式
广泛积累 — 持股数量上升且持有人增多
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 72 | +3 | 39.01M | $162.27M | +5 | −2 |
| Q1 2026 | 71 | -4 | 39.34M | $163.45M | +7 | −11 |
| Q4 2025 | 75 | 0 | 41.69M | $269.29M | +1 | −1 |
| Q3 2025 | 16 | 0 | 21.57M | $120.55M | +1 | −1 |
| Q2 2025 | 13 | +1 | 18.15M | $60.07M | +1 | — |
| Q1 2025 | 9 | -2 | 4.86M | $14.09M | — | −2 |
| Q4 2024 | 11 | +1 | 4.40M | $15.68M | +1 | — |
| Q3 2024 | 9 | +1 | 3.11M | $15.51M | +2 | −1 |
| Q2 2024 | 8 | — | 2.58M | $6.65M | — | — |
持有人 · Q2 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (被动) | 6.48M | — | $21.44M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | BlackRock ✦ (被动) | 6.48M | — | $21.44M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | BlackRock ✦ (被动) | 6.48M | — | $21.44M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | BlackRock ✦ (被动) | 6.48M | — | $21.44M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | BlackRock ✦ (被动) | 6.48M | — | $21.44M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | BlackRock ✦ (被动) | 6.48M | — | $21.44M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | BlackRock ✦ (被动) | 6.48M | — | $21.44M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | BlackRock ✦ (被动) | 6.48M | — | $21.44M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | The Vanguard Group ✦ (被动) | 4.33M | — | $14.33M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | The Vanguard Group ✦ (被动) | 4.33M | — | $14.33M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | The Vanguard Group ✦ (被动) | 4.33M | — | $14.33M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Millennium Management ✦ | 2.98M | +1054.0% | $9.86M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 13 | Geode Capital Management ✦ (被动) | 1.98M | +16.2% | $6.54M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 14 | Geode Capital Management ✦ (被动) | 1.98M | +16.2% | $6.54M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 15 | State Street Global Advisors ✦ (被动) | 1.51M | -1.0% | $4.99M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Wellington Management ✦ | 245.30K | +19.3% | $811,939 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 17 | Wellington Management ✦ | 245.30K | +19.3% | $811,939 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Wellington Management ✦ | 245.30K | +19.3% | $811,939 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 239.91K | -35.5% | $794,115 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 20 | Citadel Advisors ✦ | 152.16K | -66.9% | $503,636 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 21 | Marshall Wace ✦ | 72.58K | 新增 | $240,236 | 0.0% | New | 1 | SEC ↗ |
| 22 | Marshall Wace ✦ | 72.58K | 新增 | $240,236 | 0.0% | New | 1 | SEC ↗ |
| 23 | D. E. Shaw & Co. ✦ | 64.68K | -63.9% | $214,078 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 24 | D. E. Shaw & Co. ✦ | 64.68K | -63.9% | $214,078 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 58.75K | -54.5% | $194,460 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 58.75K | -54.5% | $194,460 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 58.75K | -54.5% | $194,460 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 28 | T. Rowe Price ✦ | 42.94K | +33.8% | $143,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 29 | Fidelity (FMR) ✦ | 2.33K | — | $7,712 | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| Marshall Wace | $240,236 | 0.0% |
| Marshall Wace | $240,236 | 0.0% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 174 持有人, 66.03M 股份, $284.02M 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Aug 17
Barber Daniel
Officer, Director · 25.00K 股 · $107,168
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Jul 27
SC 13G/A — BlackRock, Inc.
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2025 ·
方法论 ·
通过API获取此数据